Esperion Therapeutics, Inc. (ESPR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Esperion Therapeutics, Inc. reported revenue of $403.13M, up 21.3% from the prior year. The company ran a net loss, with a net margin of -5.6%. It held $465.89M in total assets against $767.85M in total liabilities.
Key ratios (FY2025)
15.0%
Operating margin
-5.6%
Net margin
+21.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $403.13M | $332.31M | $116.33M | $75.47M | $78.45M | $227.55M | $148.36M | $0 | — | — |
| Operating Income | $60.27M | $54.40M | -$155.56M | -$179.50M | -$226.73M | -$121.40M | -$93.10M | -$204.59M | -$168.98M | -$76.15M |
| Net Income | -$22.68M | -$51.74M | -$209.25M | -$233.66M | -$269.11M | -$143.55M | -$97.17M | -$201.81M | -$166.99M | -$74.98M |
| EPS (Diluted) | $-0.11 | $-0.28 | $-2.03 | $-3.52 | $-9.31 | $-5.23 | $-3.59 | — | — | — |
| Total Assets | $465.89M | $343.82M | $205.80M | $247.94M | $381.59M | $353.26M | $214.45M | $143.45M | $277.83M | $245.21M |
| Total Liabilities | $767.85M | $732.54M | $660.79M | $571.72M | $578.53M | $449.39M | $194.50M | $64.33M | $33.14M | $16.61M |
| Shareholders' Equity | -$301.96M | -$388.72M | -$454.99M | -$323.78M | -$196.94M | -$96.13M | $19.95M | $79.12M | $244.69M | $228.60M |
| Cash & Equivalents | $167.85M | $144.76M | $82.25M | $124.78M | $208.89M | $304.96M | $166.13M | $36.97M | $34.47M | $38.16M |
| Operating Cash Flow | -$13.09M | -$23.65M | -$135.49M | -$174.83M | -$263.81M | -$85.18M | -$70.34M | -$148.64M | -$131.30M | -$47.73M |
| Capital Expenditures | $0 | $317.0K | $0 | $0 | $0 | $869.0K | $953.0K | $151.0K | $19.0K | $94.0K |
| Shares Outstanding | 207.87M | 187.18M | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | — | — | — |